Ares Financial Consulting’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.2K Hold
70
– – ﹤0.01% 737
2026
Q2
$4K Hold
70
– – ﹤0.01% 767
2026
Q1
$4.01K Buy
+70
New +$4.08K ﹤0.01% 725

Other funds holding BMRN

Ares Financial Consulting's BMRN Position: Q3 2026 in Review

Ares Financial Consulting held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 70 shares worth $4.2K. The position accounts for ﹤0.01% of the portfolio, ranked #737.

Ares Financial Consulting first reported a position in BMRN in Q1 2026 and has held it in 3 quarters since. 567 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Ares Financial Consulting held 70 shares of BioMarin Pharmaceuticals worth $4.2K as of Q3 2026.
  • Ares Financial Consulting left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #737 holding.
  • Ares Financial Consulting first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 567 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.